Control of cell death in health and disease

N Kayagaki, JD Webster… - Annual Review of …, 2024 - annualreviews.org
Apoptosis, necroptosis, and pyroptosis are genetically programmed cell death mechanisms
that eliminate obsolete, damaged, infected, and self-reactive cells. Apoptosis fragments cells …

Bromodomains: a new target class for drug development

AG Cochran, AR Conery, RJ Sims III - Nature Reviews Drug Discovery, 2019 - nature.com
Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader'modules
found in proteins with varied functions, were highly tractable small-molecule targets. This is …

Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors

O Bechter, P Schöffski - Pharmacology & therapeutics, 2020 - Elsevier
Bromodomains are protein-protein interaction modules with a great diversity in terms of
number of proteins and their function. The bromodomain and extraterminal protein (BET) …

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy

ZQ Wang, ZC Zhang, YY Wu, YN Pi, SH Lou… - Signal transduction and …, 2023 - nature.com
BET proteins, which influence gene expression and contribute to the development of cancer,
are epigenetic interpreters. Thus, BET inhibitors represent a novel form of epigenetic …

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

W Li, SK Gupta, W Han, RA Kundson, S Nelson… - Journal of Hematology & …, 2019 - Springer
Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma
(DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC …

Emerging epigenetic-modulating therapies in lymphoma

D Sermer, L Pasqualucci, HG Wendel… - Nature reviews Clinical …, 2019 - nature.com
Despite considerable advances in the treatment of lymphoma, the prognosis of patients with
relapsed and/or refractory disease continues to be poor; thus, a continued need exists for …

Genetic characterization of ABT-199 sensitivity in human AML

R Bisaillon, C Moison, C Thiollier, J Krosl… - Leukemia, 2020 - nature.com
Acute myeloid leukemias (AML) with mutations in the NPM1 gene (NPM1c+) represent a
large AML subgroup with varying response to conventional treatment, highlighting the need …

Targeting BET bromodomain proteins in cancer: The example of lymphomas

F Spriano, A Stathis, F Bertoni - Pharmacology & therapeutics, 2020 - Elsevier
Abstract The Bromo-and Extra-Terminal domain (BET) family proteins act as “readers” of
acetylated histones and they are important transcription regulators. BRD2, BRD3, BRD4 and …

Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer

KH Lin, JC Rutter, A Xie, B Pardieu, ET Winn… - Nature …, 2020 - nature.com
Local adaptation directs populations towards environment-specific fitness maxima through
acquisition of positively selected traits. However, rapid environmental changes can identify …

Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL

J Zhang, Y Gu, B Chen - Cancer Management and Research, 2023 - Taylor & Francis
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's
lymphoma (NHL). 30~ 40% of DLBCL patients were resistant to the standard R-CHOP …